This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

India Coronary Stent Market Would Continue To Grow In Double Digits And Abbott Vascular (NYSE:ABT) To Lead The Market

LONDON and NEW YORK, July 1, 2014 /PRNewswire/ --

The coronary stent market in India was valued around $450 million in 2012 and it has grown at an impressive rate of 22% (2005-2012) backed by a rise in PCIs (Percutaneous Coronary Intervention) which is resulted from a surge in cardiovascular disease (CVD), an improvement in healthcare infrastructure and services and an increase in disposable income. An increasing penetration of DES, which is above 90%, has also boosted the market.

The market is lead by Abbott Vascular (NYSE:ABT), followed by Boston Scientific (NYSE:BSX). Other key players operating in the segment are Medtronic, Inc. (NYSE:MDT), Biotronik, Sahajanand Medical Technologies, Meril Life Sciences and Translumina Therapeutics. Johnson and Johnson's (NYSE:JNJ) Cordis stopped selling its stents from 20011. Cordis's market was grabbed by Abbott, Medtronic and other players. Bioabsorbable stent ABSORB, which was recently launched by Abbott Vascular, has garnered a considerable traction among the medical fraternity despite its high cost compared with other stents available in the market. The patients opting for ABSORB are financially sound or have either health insurance or are entitled for reimbursement. Abbott is aggressively chasing the market through a direct-to-consumer approach (DTC).

The coronary stent market in the country will continue to grow at a faster pace due to new and upcoming private hospitals, government initiatives to improve healthcare access, an increasing number of interventional cardiologists, an explosion of healthcare insurance and a growth in usage of high value bioabsorbable stents. The anticipated progression can be attributed to growth in elderly population, improved life expectancy, lifestyle diseases and associated complications like diabetes, hypertension and obesity.

The majority of population in need of stents is not covered under health insurance or do not get reimbursements which limits the market. However, patients under the poverty line are sponsored for healthcare insurance through the state government or insurance under public and private partnership. Some state governments have put a cap on the pricing of stents; though it may limit the market in terms of value but may help increase penetration of stents. Some state governments have put a cap on the value of stents; though this may help increase penetration of stents, it may limit the market in terms of value.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs